FDA Authorises RSV Immunisation for Expectant Mothers

The FDA has approved Pfizer’s respiratory syncytial virus vaccine to shield babies through the ongoing vaccination of expectant mothers.

RSV causes a number of minor symptoms resembling a cold. Although the majority of individuals get better within a week or so, it may result in serious sickness for babies.

Abrysvo has been cleared by the FDA for use in pregnant women who are 8 to 9 months along in their pregnancy to avoid lower respiratory tract disease (LTRD) and serious cases of this in newborns.

Head Scientific Officer at Pfizer, Annaliesa Anderson stated, “Abrysvo’s approval as the first and only maternal immunisation to help protect newborns immediately at birth through six months from RSV marks a significant milestone for the scientific community and for public health.”

CEO of FDA’s Centre for Biologics Evaluation and Research added, “This approval provides an option for healthcare providers and pregnant individuals to protect infants from this potentially life-threatening disease.”

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved